GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

被引：0
|
作者：
Norrbacka, K. [1 ]
Sicras-Mainar, A. [2 ]
Hernandez, I [3 ]
Tofe-Povedano, S. [4 ]
Diaz Cerezo, S. [5 ]
Artime, E. [5 ]
Lebrec, J. [6 ]
Romera, I [5 ]
机构：
[1] Eli Lilly & Co, Helsinki, Finland
[2] Real Life Data SLU, Barcelona, Spain
[3] Real Life Data SLU, Madrid, Spain
[4] Univ Hosp Son Espases Palma de Mallorca, Palma De Mallorca, Spain
[5] Lilly Spain, Alcobendas, Spain
[6] HaaPACS GmbH, Schriesheim, Germany
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB119
引用
收藏
页码：S594 / S594
页数：1
相关论文
共 50 条
  • [1] Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
    Norrbacka, Kirsi
    Sicras-Mainar, Antoni
    Lebrec, Jeremie
    Artime, Esther
    Diaz, Silvia
    Tofe-Povedano, Santiago
    Hernandez, Ignacio
    Romera, Irene
    DIABETES THERAPY, 2021, 12 (05) : 1535 - 1551
  • [2] Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
    Kirsi Norrbacka
    Antoni Sicras-Mainar
    Jeremie Lebrec
    Esther Artime
    Silvia Díaz
    Santiago Tofé-Povedano
    Ignacio Hernández
    Irene Romera
    Diabetes Therapy, 2021, 12 : 1535 - 1551
  • [3] Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
    Hansen, K. B.
    Knop, F. K.
    Holst, J. J.
    Vilsboll, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1154 - 1160
  • [4] Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Harris, Kira B.
    McCarty, Delilah J.
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 3 - 18
  • [5] Adherence to Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Patients with Type 2 Diabetes Mellitus (T2DM)
    Johnston, Stephen
    Nguyen, Hiep
    Felber, Eugene
    Cappell, Katherine
    Nelson, James K.
    Chu, Bong-Chul
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A604 - A604
  • [6] Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world
    Franch-Nadal, Josep
    Granado-Casas, Minerva
    Mata-Cases, Manel
    Ortega, Emilio
    Vlacho, Bogdan
    Mauricio, Didac
    PRIMARY CARE DIABETES, 2022, 16 (06) : 810 - 817
  • [7] Glucagon-Like Peptide-1 Receptor Agonists Reduction in Stroke Type 2 DM Patients
    Alhawyan, Fatmah Salem
    Althobaiti, Mohammed Adel
    Alnami, Hashim Yahya
    Allahafi, Hadeel Ibrahim
    Almalky, Ayman Jamaan
    Al Johani, Sultan Ahmed
    Shiban, Rokayah Hussain
    Saddah, Mohammed Ahmed
    Alamrah, Hussam Mohammed
    Aljuhani, Moayad Zeyad
    Alfallaj, Ebtehal Hamid
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2020, 10 (05): : 122 - 128
  • [8] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Ju-Ming Lu
    Advances in Therapy, 2019, 36 : 798 - 805
  • [9] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [10] Effectiveness of glucagon-like peptide-1 agonists in type 2 diabetes
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (03): : 359 - 360
12345